Company / Return on Equity (ROE)
CHAMPIONS ONCOLOGY, INC. Return on Equity (ROE) History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Return on Equity (ROE)
-192.9%
FY2025
5-year range
-192.9% / 6.0%
FY2021-FY2025
Trend
-
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
CHAMPIONS ONCOLOGY, INC. reports negative total equity of -192.9% in FY2025. Negative equity can occur when accumulated losses exceed contributed capital, as reported in the balance sheet from the SEC filing.
Based on SEC 10-K filings.
-192.9% in FY2025 with a 5-year CAGR of -200.0%.
Declined from 4.9% to -192.9% over the past 3 years.
Return on Equity (ROE) over time
Growth rates
- 3-Year Change
- -197.8pp
- 5-Year Change
- -200.0pp
- 10-Year Change
- -
Key checks
Key Insights
- Peak return on equity (roe) was recorded in FY2020.
- Lowest return on equity (roe) in the period was in FY2017.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -1.23 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Return on Equity (ROE)Value | YoY GrowthYoY |
|---|---|---|
| FY2025 | -192.9% | - |
| FY2024 | - | - |
| FY2023 | 6.0% | +23.6% |
| FY2022 | 4.9% | +111.9% |
| FY2021 | -41.0% | -678.2% |
| FY2020 | 7.1% | +107.2% |
| FY2019 | -97.9% | +94.3% |
| FY2018 | -1721.0% | +60.8% |
| FY2017 | -4388.9% | -2591.7% |
| FY2016 | -163.1% | +29.6% |
As of FY2025 · SEC 10-K · Updated Jun 24, 2026